Aurobindo Pharma Q3FY26 results: Net profit rises 8% to ₹910 crore | Company Results

Aurobindo Pharma on Monday said its consolidated net profit rose 8 per cent year-on-year to ₹910 crore for the December quarter, driven by robust sales in Europe and the United States.

The Hyderabad-based pharmaceutical major reported a net profit of ₹846 crore for the October-December period of the last financial year.

Total revenue from operations increased to ₹8,646 crore during the quarter from ₹7,979 crore in the year-ago period, the pharmaceutical company said in a statement.

“The third quarter reflected steady execution in Aurobindo’s core businesses, supported by stable demand and the strength of our diversified product portfolio in key markets including the US and Europe,” Aurobindo Pharma Vice Chairman and Managing Director K Nithyananda Reddy said.

Growth remained measured, with a continued focus on operational discipline and a balanced approach to growth and profitability, he added.

“As we progress our strategic initiatives, we remain cautious but confident in our ability to support sustainable value creation over the medium term,” Reddy said.

Shares of the company ended Monday 0.85 per cent higher at ₹1,201.25 apiece on the BSE.